Empagliflozin Versus Metformin for Glucose Variability and Metabolic Outcomes in Drug-Naïve Type 2 Diabetes
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:
• Participants were eligible if they had T2D with an HbA1c between 6.5% and 10.0%, were between 20 and 75 years of age, and had not received any anti-diabetic medications for at least eight weeks prior to screening.
Locations
Other Locations
Republic of Korea
SNUBH
RECRUITING
Seongnam
Contact Information
Primary
Ji Young Byun Administrative staff, MS
65423@snubh.org
82-31-787-7035
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 46
Treatments
Active_comparator: Standard
Metformin therapy
Experimental: Experimental
Empagliflozin therapy
Related Therapeutic Areas
Sponsors
Leads: Seoul National University Bundang Hospital